South, Atlanta, Georgia 30341. (Exit Center, Vanderbilt Building, 1st Floor, Prevention and Control (NCIPC), CDC, Koger 12, 1996. Closed: 2:15 p.m.±5 p.m., February 12, 1996. Committee: Conference Call Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following conference call meeting.

Name: Injury Research Grant Review Committee (IRGRC).

Time and Date: 2 p.m.±5 p.m., February 12, 1996.

Place: National Center for Injury Prevention and Control (NCIPC), CDC, Vanderbilt Center, Vanderbilt Building, 1st Floor, Conference Room 1006, 2939 Flowers Road, South, Atlanta, Georgia 30341. (Exit Chambly-Tucker Road off I-85.)

Status: Open: 2 p.m.±2:15 p.m., February 12, 1996. Closed: 2:15 p.m.±5 p.m., February 12, 1996.

Purpose: This committee is charged with advising the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the scientific merit and technical feasibility of grant applications relating to the support of injury control research projects and injury prevention research centers.

Matters To Be Discussed: Agenda items for the meeting will include announcements, discussion of review procedures, future meeting dates, and review of grant applications.

Beginning at 2:15 p.m., through 5 p.m., February 12, the Committee will meet to conduct a review of grant applications. This portion of the meeting will be closed to the public in accordance with provisions set forth in section 552(b)(c) (4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92-463. Agenda items are subject to change as priorities dictate.

Contact Person for More Information:
Richard W. Sattin, M.D., Executive Secretary, IRGRC, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway, NE, M/S K58, Atlanta, Georgia 30341-3724, telephone (770) 488-4580.

Dated: January 23, 1996.

Julia M. Fuller,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

Dated: January 22, 1996.

Julia M. Fuller,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

Dated: January 22, 1996.

Savannah River Site Environmental Dose Reconstruction Project: Public Workshops

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Savannah River Site Environmental Dose Reconstruction Project: Public Workshops

Date: Wednesday, February 14, 1996.

Time: 7 p.m.±9 p.m.

Place: Holiday Inn Express, 1350 Whiskey Road, Aiken, South Carolina 29803.


Time: 7 p.m.±9 p.m.

Place: Hilton—The DeSoto, 15 East Liberty Street, Savannah, Georgia 31401.

Status: Open to the public for observation and comment, limited only by the space available. The meeting room will accommodate approximately 50 people.

Background: Under a Memorandum of Understanding (MOU) signed in December 1990 with the Department of Energy (DOE), the Department of Health and Human Services (HHS) has given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production and use.

HHS delegated program responsibility to CDC.

In addition, an MOU was signed in October 1990 and renewed in November 1992 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR’s public health activities at DOE site required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA, or “Superfund”). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public, and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicologic profiles.

Purpose: The purpose of these meetings is to support research which evaluates past releases of radioactive materials and chemicals from the SRS to the surrounding environment. The Project has already undergone a first phase. Phase I involved searching the site to identify and retrieve important documents to be used for dose reconstruction. Phase II will use this information to calculate chemical and radiological source terms and identify possible intake pathways (eating, drinking, and inhalation) for people who have lived in the SRS area.

Agenda items are identical for each meeting, and subject to change as priorities dictate.

Contact Person for More Information: Paul G. Renard, Project Manager, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, (F-35), Atlanta, Georgia 30341-3724, telephone 770/488-7040, FAX 770/488-7044.

Dated: January 22, 1996.

Julia M. Fuller,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

Dated: January 22, 1996.

Food and Drug Administration

[Docket No. 96N-0012]

Animal Drug Export; ANIPRYL® Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Deprenyl Animal Health, Inc., has filed an application requesting approval for export of the animal drug ANIPRYL® (l-leagenine hydrochloride, L-Dopa hydrochloride) tablets to Canada.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of nonfood animal drugs under the Drug Export Amendments of 1996 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Gregory S. Gates, Center for Veterinary Medicine (HFV–114), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1617.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the